Restart Life Sciences Corp.
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. … Read more
Restart Life Sciences Corp. (NMLSD) - Net Assets
Latest net assets as of June 2025: $62.67K USD
Based on the latest financial reports, Restart Life Sciences Corp. (NMLSD) has net assets worth $62.67K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($277.56K) and total liabilities ($214.89K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $62.67K |
| % of Total Assets | 22.58% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 930.44 |
Restart Life Sciences Corp. - Net Assets Trend (2020–2024)
This chart illustrates how Restart Life Sciences Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Restart Life Sciences Corp. (2020–2024)
The table below shows the annual net assets of Restart Life Sciences Corp. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-299.07K | +63.11% |
| 2023-12-31 | $-810.60K | -2060.63% |
| 2022-12-31 | $41.34K | -90.99% |
| 2021-12-31 | $459.10K | -82.76% |
| 2020-12-31 | $2.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Restart Life Sciences Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 615018200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $58.77 Million | % |
| Total Equity | $-299.07K | 100.00% |
Restart Life Sciences Corp. Competitors by Market Cap
The table below lists competitors of Restart Life Sciences Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thunderbird Minerals Corp.
V:BIRD
|
$539.80 |
|
World Chess PLC
LSE:CHSS
|
$540.18 |
|
Next10 Inc
PINK:NXTN
|
$540.54 |
|
Liminatus Pharma, Inc. Warrants
NASDAQ:LIMNW
|
$541.98 |
|
Biztech Konsulting SA
WAR:BTK
|
$539.04 |
|
Neovacs S.A.
PA:ALNEV
|
$537.87 |
|
Reem Capital Corp.
V:REEM-P
|
$537.29 |
|
Theracryf Plc
LSE:TCF
|
$536.01 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Restart Life Sciences Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -810,603 to -299,071, a change of 511,532.
- Net income of 224,745 contributed positively to equity growth.
- Other factors increased equity by 286,787.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $224.75K | +75.15% |
| Other Changes | $286.79K | +95.89% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Restart Life Sciences Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.12 | $0.05 | x |
| 2021-12-31 | $0.04 | $0.05 | x |
| 2022-12-31 | $0.00 | $0.05 | x |
| 2023-12-31 | $-0.06 | $0.05 | x |
| 2024-12-31 | $-0.02 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Restart Life Sciences Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1499.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -947.35% | -219950.23% | 0.00x | 1.14x | $-25.50 Million |
| 2021 | -584.75% | 0.00% | 0.00x | 1.92x | $-2.73 Million |
| 2022 | -5964.31% | 0.00% | 0.00x | 7.18x | $-2.47 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.14 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $254.65K |
Industry Comparison
This section compares Restart Life Sciences Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Restart Life Sciences Corp. (NMLSD) | $62.67K | -947.35% | 3.43x | $539.72 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |